Comments
Jordan head-quartered Hikma Pharmaceuticals Plc has agreed to acquire a minority interest in privately-held Unimark, a maker of active pharmaceutical ingredients and API intermediates, for a consideration of $33.3 million.
The $730-million Hikma, a maker of finished forms of medicine, would be a significant minority share-holder in Unimark, its Executive Mr Yogesh Parikh, told Business Line , without giving details.
Hikma will source pharmaceutical ingredients from Unimark, while the latter looks to use the marketing arm of Hikma in the US for future distribution of Unimark's branded generic drugs, he added.
Unimark's product range includes betalactams, cephalosporins, carbapenems in therapeutic segments including cardiovascular, anti-asthma and anti-infectives.
Unimark operates three API facilities, two of which are US FDA approved, and two research centres, in India.
A generic-drug company, Hikma has a strong presence in the West-Asian and North African markets.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.